PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
摘要:
The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
[EN] SOS1 INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR DE SOS1 ET SON UTILISATION<br/>[KO] SOS1 억제제 및 이의 용도
申请人:KANAPH THERAPEUTICS INC
公开号:WO2023022497A1
公开(公告)日:2023-02-23
화학식 I의 신규 화합물 및 이의 SOS1과 관련된 질환의 예방 또는 치료 용도를 제공한다. 본 발명의 일 양상의 신규 화합물은 SOS1와 RAS 패밀리 단백질 또는 SOS1과 RAC1의 상호작용을 저해함으로써 암 및 RAS 병증 등의 SOS1 매개된 질환의 예방 또는 치료에 유용하다.
effective methodology for the cross-coupling of heteroaryl iodides with NN–AuPPh3 at room temperature is reported. The protocol is based on a novel catalytic system consisting of Pd2(dba)3·CHCl3 and the phosphine ligand MeCgPPh having an adamantane-like framework. The present protocol was found to be well compatible with various heteroaryl iodides, thus opening new horizons in directed synthesis of functionalized